Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule

Immunobiology

Volumn 217, Issue 1, 2012, Pages 17-27

  Atassi, M Zouhair ^a   Jankovic, Joseph ^a   Steward, Lance E ^b   Aoki, K Roger ^b   Dolimbek, Behzod Z ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

Author keywords

Antigenic sites; Blocking antibodies; Botulinum neurotoxin A; Botulinum neurotoxin B; Cervical dystonia; Epitopes; Immunoresistance; Synthetic peptides

Indexed keywords

BOTULINUM TOXIN B; MAJOR HISTOCOMPATIBILITY ANTIGEN;

AMINO ACID COMPOSITION; AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN RECOGNITION; ANTIGEN STRUCTURE; ARTICLE; CERVICAL DYSTONIA; CONTROLLED STUDY; ENZYME ACTIVE SITE; EPITOPE MAPPING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; TOXIN STRUCTURE; TREATMENT DURATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, BLOCKING; BINDING SITES, ANTIBODY; BOTULINUM TOXINS; BOTULINUM TOXINS, TYPE A; CLOSTRIDIUM BOTULINUM; EPITOPE MAPPING; HUMANS; IMMUNE SERA; IMMUNITY, HUMORAL; MICE; MICE, INBRED ICR; MOLECULAR SEQUENCE DATA; NEUROTOXINS; PEPTIDE FRAGMENTS; PROTEIN BINDING; TORTICOLLIS; TREATMENT FAILURE;

EID: 82155172909     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2011.08.009     Document Type: Article

References (59)

1. Adekar S.P., Takahashi T., Jones R.M., Al-Saleem F.H., Ancharski D.M., Root M.J., Kapadnis B.P., Simpson L.L., Dessain S.K. Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS One 2008, 3(8):e3023.
2. Atassi M.Z. Antigenic structure of myoglobin. The complete immunochemical anatomy of a protein and conclusions relating to antigenic structures of proteins. Immunochemistry 1975, 12:423-438.
3. Atassi M.Z. Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking or protein binding sites. Eur. J. Biochem. 1984, 145:1-20.
4. Atassi M.Z. Strategies for localization of protein biding sites. Mod. Methods Protein Chem. 1988, vol. 3. Walter de Gruyter, Berlin, pp. 1-40.
5. Atassi M.Z. Basic immunological aspects of botulinum toxin therapy. Mov. Disord. 2004, 19(Suppl. 8):S68-S84.
6. Atassi M.Z., Oshima M. Structure, activity and immune (T and B cell) recognition of botulinum neurotoxin. Crit. Rev. Immunol. 1999, 19:219-260.
7. Atassi M.Z., Smith J.A. A Proposal for the nomenclature of antigen sites in peptides and proteins. Immunochemistry 1978, 15:609-610.
8. Atassi M.Z., Dolimbek G.S., Deitiker P.R., Aoki K.R., Dolimbek B.Z. Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A. Mol. Immunol. 2005, 42:1509-1520.
9. Atassi M.Z., Manshouri T., Sakata S. Localization and synthesis of the hormone-binding regions of the human thyrotropin receptor. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:3613-3617.
10. Atassi M.Z. On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 2006, 52:1891-1895.
11. Atassi M.Z., Dolimbek B.Z., Jankovic J., Steward L.E., Aoki K.R. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol. Immunol. 2008, 45:3878-3888.
12. Atassi M.Z., Dolimbek B.Z., Jankovic J., Steward L.E., Aoki K.R. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology 2011, 216:782-792.
13. Bandyopadhyay S., Clark A.W., Das Gupta B., Sathyamoorthy V. Role of the heavy and light chains of botulinum neurotoxin in neuromuscular paralysis. J. Biol. Chem. 1987, 262:2660-2663.
14. Binder W.J., Brin M.F., Blitzer A., Pogoda J.M. Botulinum toxin type A (BOTOX) for treatment of migraine. Dis. Mon. 2002, 48:323-335.
15. Breidenbach M.A., Brunger A.T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 2004, 432:925-929.
16. Brunger A.T., Rummel A. Receptor and substrate interactions of clostridial neurotoxins. Toxicon 2009, 54:550-560.
17. Byrne M.P., Smith L.A. Development of vaccines for prevention of botulism. Biochimie 2000, 82:955-966.
18. Campbell K.D., Collins M.D., East A.K. Gene probes for identification of the botulinal neurotoxin gene and specific identification of neurotoxin types B, E, and F. J. Clin. Microbiol. 1993, 31:2255-2262. Also, B3: C. botulinum (strain non-proteolytic Eklund 2B) gene for neurotoxin type B. Accession # X70819. (ref. same as B2); B4: C. botulinum (strain proteolytic B) gene for neurotoxin type B. Accession # X70817. (ref. same as B2); B5: Clostridium botulinum neurotoxin type B (botB) gene, complete cds Accession # M81186.
19. Chai Q., Arndt J.W., Dong M., Tepp W.H., Johnson E.A., Chapman E.R., Stevens R.C. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 2006, 444:1096-1100.
20. Cheng L.W., Stanker L.H., Henderson T.D., Lou J., Marks J.D. Antibody protection against botulinum neurotoxin intoxication in mice. Infect. Immun. 2009, 77(10):4305-4313.
21. David C.S., Atassi M.Z. Genetic control and intersite influences on the immune response to sperm whale myoglobin. Adv. Exp. Med. Biol. 1982, 150:97-126.
22. Diamond A., Jankovic J. Botulinum toxin in dermatology - beyond wrinkles and sweat. J. Cosmet. Dermatol. 2006, 5:169.
23. Dolimbek B.Z., Jankovic J., Atassi M.Z. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol. Invest. 2002, 31:247-262.
24. Dolimbek G.S., Dolimbek B.Z., Aoki K.R., Atassi M.Z. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol. Invest. 2005, 34:119-142.
25. Dolimbek B.Z., Aoki K.R., Steward L.E., Jankovic J., Atassi M.Z. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol. Immunol. 2007, 44:1029-1041. (Epub May 2, 2006).
26. Dolimbek B.Z., Steward L.E., Aoki K.R., Atassi M.Z. Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin A. Antigenic structure of the entire toxin. Immunobiology 2011, 216:698-706.
27. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312:592-596.
28. Foran P., Shone C.C., Dolly J.O. Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments. Biochemistry 1994, 33:15365-15374.
29. Fu F.N., Lomneth R.B., Cai S., Singh B.R. Role of zinc in the structure and toxic activity of botulinum neurotoxin. Biochemistry 1998, 37:5267-5278.
30. Göschel H., Wohlfarth K., Frevert J., Dengler R., Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing Abs - therapeutic consequences. Exp. Neurol. 1997, 147:96-102.
31. Gui D., Rossi S., Runfola M., Magalini S.C. Review article: botulinum toxin in the therapy of gastrointestinal motility disorders. Aliment. Pharmacol. Ther. 2003, 18:1-16.
32. Hutson R.A., Collins M.D., East A.K., Thompson D.E. Nucleotide sequence of the gene coding for non-proteolytic Clostridium botulinum type B neurotoxin: comparison with other clostridial neurotoxins. Curr. Microbiol. 1994, 28:101-110.
33. Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov. Disord. 2004, 19(Suppl. 8):S109-S115.
34. Jankovic J. Treatment of dystonia. Lancet Neurol. 2006, 5:864-872.
35. Jankovic J., Hunter C., Dolimbek B.Z., Dolimbek G.S., Adler C.H., Brashear A., Comella C.L., Gordon M., Riley D.E., Sethi K., Singer C., Stacy M., Tarsy D., Atassi M.Z. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 2006, 67:2233-2235.
36. Jin R., Rummel A., Binz T., Brunger A.T. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 2006, 444:1092-1095.
37. Kazim A.L., Atassi M.Z. A novel and comprehensive synthetic approach for the elucidation of protein antigenic structures. Determination of the full antigenic profile of the alpha-chain of human haemoglobin. Biochem. J. 1980, 191:261-264.
38. Kazim A.L., Atassi M.Z. Structurally inherent antigenic sites. Localization of the antigenic sites of the alpha-chain of human haemoglobin in three host species by a comprehensive synthetic approach. Biochem. J. 1982, 203:201-208.
39. Kazim A.L., Atassi M.Z. Prediction and confirmation by synthesis of two antigenic sites in human haemoglobin by extrapolation from the known antigenic structure of sperm whale myoglobin. Biochem. J. 1977, 167:275-278.
40. Kozaki S., Miki A., Kamata Y., Ogasawara J., Sakaguchi G. Immunological characterization of papain-induced fragments of Clostridium botulinum type A neurotoxin and interaction of the fragments with brain synaptosomes. Infect. Immun. 1989, 57:2634-2639.
41. Lacy D.B., Tepp W., Cohen A.C., DasGupta B.R., Stevens R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5:898-902.
42. Li L., Singh B.R. In vitro translation of type A Clostridium botulinum neurotoxin heavy chain and analysis of its binding to rat synaptosomes. J. Protein Chem. 1999, 18:89-95.
43. Mahrhold S., Rummel A., Bigalke H., Davletov B., Binz T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 2006, 580:2011-2014.
44. Maruta T., Dolimbek B.Z., Aoki K.R., Atassi M.Z. Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: a new assay for blocking and non-blocking antibodies. J. Neurosci. Methods 2006, 151:90-96.
45. Maruta T., Dolimbek B.Z., Aoki K.R., Steward L.E., Atassi M.Z. Mapping of the synaptosome-binding regions on the heavy chain of botulinum neurotoxin A by synthetic overlapping peptides encompassing the entire chain. Protein J. 2004, 23:539-552.
46. Nishiki T., Tokuyama Y., Kamata Y., Nemoto Y., Yoshida A., Sekiguchi M., Takahashi M., Kozaki S. Binding of botulinum type B neurotoxin to Chinese hamster ovary cells transfected with rat synaptotagmin II cDNA. Neurosci. Lett. 1996, 208:105-108.
47. Nishiki T., Tokuyama Y., Kamata Y., Nemoto Y., Yoshida A., Sato K., Sekiguchi M., Takahashi M., Kozaki S. The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett. 1996, 378:253-257.
48. Okuda K., Christadoss P.R., Twining S.S., Atassi M.Z., David C.S. Genetic control of immune response to sperm whale myoglobin in mice. I. T lymphocyte proliferative response under H-2-linked Ir gene control. J. Immunol. 1978, 121:866-868.
49. Okuda K., Sakata S., Atassi M.Z., David C.S. Genetic control of the immune response to hen's egg-white lysozyme in mice. I. Antibody and T-lymphocyte proliferative responses to the native protein. J. Immunogenet. 1979, 6:447-652.
50. Okuda K., Twining S.S., David C.S., Atassi M.Z. Genetic control of immune response to sperm whale myoglobin in mice. II. T lymphocyte proliferative response to the synthetic antigenic sites. J. Immunol. 1979, 123:182-188.
51. Pellizzari R., Rossetto O., Lozzi L., Giovedi S., Johnson E., Shone C.C., Montecucco C. Structural determinants of the specificity for synaptic vesicle-associated membrane protein/synaptobrevin of tetanus and botulinum type B and G neurotoxins. J. Biol. Chem. 1996, 271:20353-20358.
52. Rossetto O., Schiavo G., Montecucco C., Poulain B., Deloye F., Lozzi L., Shone C.C. SNARE motif and neurotoxins. Nature 1994, 372:415-416.
53. Salzameda N.T., Eubanks L.M., Zakhari J.S., Tsuchikama K., DeNunzio N.J., Allen K.N., Hixon M.S., Janda K.D. A cross-over inhibitor of the botulinum neurotoxin light chain B: a natural product implicating an exosite mechanism of action. Chem. Commun. 2011, 47:1713-1715.
54. Schiavo G., Rossetto O., Santucci A., DasGupta B.R., Montecucco C. Botulinum neurotoxins are zinc proteins. J. Biol. Chem. 1992, 267:23479-23483.
55. Simpson L.L. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu. Rev. Pharmacol. Toxicol. 1986, 26:427-453.
56. Swaminathan S., Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 2000, 7:693-699.
57. Takahashi T., Joshi S.G., Al-Saleem F., Ancharski D., Singh A., Nasser Z., Simpson L.L. Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin. Vaccine 2009, 27:2616-2624.
58. Turton K., Chaddock J.A., Acharya K.R. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem. Sci. 2002, 27:552-558.
59. Yoshioka N., Atassi M.Z. Antigenic structure of human haemoglobin: localization of the antigenic sites of the β-chain in three host species by synthetic overlapping peptides representing the entire chain. Biochem. J. 1986, 234:441-447.